FC
BEAM icon

Fairscale Capital’s Beam Therapeutics BEAM Stock Holding History

Fairscale Capital’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50
Closed -$1.39K – 438
2025
Q4 		$1.39K Hold
50
– – ﹤0.01% 389
2025
Q3 		$1.21K Hold
50
– – ﹤0.01% 414
2025
Q2 		$986 Hold
50
– – ﹤0.01% 413
2025
Q1 		$977 Hold
50
– – ﹤0.01% 321
2024
Q4 		$1.24K Hold
50
– – ﹤0.01% 321
2024
Q3 		$1.23K Hold
50
– – ﹤0.01% 319
2024
Q2 		$1.36K Buy
+50
New +$1.23K ﹤0.01% 322

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Fairscale Capital's BEAM Position: Q1 2026 in Review

Fairscale Capital sold out of Beam Therapeutics (BEAM) in Q1 2026, closing a stake of 50 shares — an estimated $1.39K sold.

Fairscale Capital first reported a position in BEAM in Q2 2024 and held it in 7 quarters. The position peaked at $1.39K in Q4 2025. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Fairscale Capital reported no remaining Beam Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Fairscale Capital sold 50 Beam Therapeutics shares in Q1 2026, an estimated $1.39K.
  • Fairscale Capital first reported a position in Beam Therapeutics in Q2 2024 and held it in 7 quarters.
  • Fairscale Capital's Beam Therapeutics position peaked at $1.39K in Q4 2025.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Fairscale Capital's 13F filing for Q1 2026, filed 11 May 2026.